ãããã¯ã¹ã®å¹æã¯ãã€ãŸã§ïŒéšäœå¥ã®æç¶æéããŒã¿ãè«æã§è§£èª¬
ã3ã¶æãããã§ããããââã¯ãªããã¯ã§è¿ã£ãŠãããã®çãã«ãããªãã¯ããæºè¶³ããŠããªãã¯ãã§ãã
ãªããªããããªããæ¬åœã«ç¥ãããã®ã¯ãèªåã®éšäœã«ãèªåã®æ§å¥ã§ãã©ã®è£œå€ã䜿ãã°ãäœé±éæã€ã®ãããšããå ·äœçãªæ°åã ããã§ãã
å®ã¯å»åŠè«æã«ã¯ããã®çãããã§ã«åºãŠããŸããçéãªãæå€§24.2é±ãç®å°»ãªãæå€§157æ¥ãå£åšãã¯ãã¢ã«ãã³é žãçµã¿åããããšæç¶æéã1.5å以äžã«å»¶ã³ãââããã¯ãã¹ãŠãæ»èªæžã¿èšåºç ç©¶ã®ããŒã¿ã§ãã
ãã®èšäºã§ã¯ã以äžã®4ç¹ãè«æããŒã¿ã®ã¿ã§è§£èª¬ããŸãã
- ãããã¯ã¹ïŒãããªãã¹ããã·ã³ïŒã®åºæ¬çãªäœçšæ©åºãšå¹æãåããã¡ã«ããºã
- çéãç®å°»ãé¡ãå£åšããå¬çïŒãšã©ïŒãªã©ãéšäœå¥ã®è©³çްãªå¹ææç¶æé
- æäžéïŒåäœæ°ïŒã補å€ã®çš®é¡ã«ãã£ãŠæç¶æéãã©ãå€åããã®ã
- æ§å¥ã«ãã广æç¶æéã®éã
ã人ãããããã§ã¯çŽåŸã§ããªãæ¹ã®ããã«ãäžçäžã®ä¿¡é Œã§ããå»åŠè«æãã·ã¹ãããã£ãã¯ã¬ãã¥ãŒã®ããŒã¿ã®ã¿ãçšããŠãéšäœå¥ã»è£œå€å¥ã®ãããã¯ã¹æç¶æéã培åºçã«è§£èª¬ããŸãã
ããããããªã广ã¯åããïŒââäœçšæ©åºãšæç¶ã®ã¡ã«ããºã
ãããçè§£ããªããšãããªãèªåã ãæ©ãåããã®ãããæ°žé ã«ããããŸããã
BontAãçèå ã«æ³šå°ãããšãæ¯çŽ ãç¥çµçµæ«ã«æ¡æ£ããŠçµåããç¥çµäŒéç©è³ªã§ããã¢ã»ãã«ã³ãªã³ã®æŸåºãé²ããŸããããã«ãããç¥çµçæ¥åéšã§ã®äœçšãé»å®³ãããçµæãšããŠçèãåçž®ããªããªãã衚æ ãžã¯ïŒåçã·ã¯ïŒã圢æãããªããªããŸãïŒBerry 2012ïŒã
çæŽ»åã®å®å šãªæ¬ åŠã¯ã泚å°åŸããã5æ¥ãã15æ¥ïŒBerry 2012ïŒã§çºçããŸããç¹å®ã®é¡é¢çãåçž®ããªããªããããã·ã¯ãæžã£ããšå®æã§ããã®ã§ãïŒFagien 2003ïŒã
ã§ã¯ããªãæ°ã¶æã§å¹æãåããã®ãã
çãã¯ã·ã³ãã«ã§ãââç¥çµããåçãããããã§ããååŠçãªå¹æã«ããçèã®èçž®ã¯ãç¥çµçµæ«ã«ããããçºèœïŒsproutingïŒããšããŠç¥ãããåçããã»ã¹ãåŒãèµ·ãããŸãããã®åçããã»ã¹ã¯120æ¥éæç¶ããç¥çµçæ¥åéšã«æ°ããªçµæ«ãçã¿åºããæçµçã«çèã®æŽ»åãå埩ãããŸãããã®ãããªã¡ã«ããºã ããããããèšåºçãªæ²»çå¹æã®æç¶æéã¯éåžž3ã¶æãã6ã¶æïŒBerry 2012ïŒã®ç¯å²ãšãªããŸãã
ã¡ã«ããºã ãæŒããããšããã§ãããããéšäœå¥ã®å ·äœçãªæ°åãèŠãŠãããŸãããã
ãçéãæãç ç©¶ããŒã¿ãè±å¯ãªéšäœââ17.6é±ã24.2é±
çŸå®¹å»çã«ãããŠæãäžè¬çãªæ²»çéšäœã®1ã€ïŒCochrane Review 2021ïŒããçéã®ããã§ãããã®ãããããŒã¿ãæãå å®ããŠããŸãã
ãŸããããªãããåžžèãã ãšæã£ãŠããããšã厩ãããŠãã ããã
ãé«çšéïŒé·æã¡ãã¯æ¬åœãïŒ20Uã80Uã®æ¯èŒããŒã¿
çšéã4åã«ããã°ãæç¶æéã4åã«ãªãââæ®å¿µãªãããããã¯ãªããŸãããæ°åãèŠãã°äžç®çç¶ã§ãã
- OnabotulinumtoxinA 20UïŒCarruthers 2005bïŒïŒå¹³åæç¶æé 17.6é±
- åè£œå€ 40UïŒCarruthers 2005bïŒïŒ21.7é±
- åè£œå€ 60UïŒCarruthers 2005aïŒïŒ22.8é±
- åè£œå€ 80UïŒCarruthers 2005aïŒïŒ24.2é±
20U â 80Uãšçšéã4åã«ããŠããæç¶æéã¯17.6é± â 24.2é±ã®å»¶é·ã«ãšã©ãŸããŸããã€ãŸããé«çšéãæäžããã°ããã ãé·ã广ãç¶ããã®ã®ãåçã«åå¢ããããã§ã¯ãããŸããããããããæãŠã°é·æã¡ããšããåçŽãªè©±ã§ã¯ãªãã®ã§ãã
補å€ã®çš®é¡ã«ããçéã®æç¶æéã®éã
次ã«ã補å€ããšã®ããŒã¿ã§ãããããã¯ã¹ã«ã¯è€æ°ã®è£œå€ãååšããããããã§æç¶æéã®ããŒã¿ãå ±åãããŠããŸãã
IncobotulinumtoxinAïŒXEOMIN®ãªã©ïŒ
æç¶æéã¯å¥³æ§ã§20.8é±ïŒ146.12æ¥ïŒãç·æ§ã§17.3é±ïŒ121.14æ¥ïŒãåç ç©¶ã«ãããOnabotulinumtoxinAã®æç¶æéã¯ã女æ§ã§20é±ïŒ140.65æ¥ïŒãç·æ§ã§16.6é±ïŒRappl 2013ïŒïŒ116.61æ¥ïŒã§ããã䞡補å€ã¯éåžžã«è¿ãæç¶æéã瀺ããŠããŸãã
AbobotulinumtoxinAïŒDysport®ãªã©ïŒ
- ãã©ã»ããšæ¯èŒããç ç©¶ã§ã¯ãæç¶æéã®äžå€®å€ã¯12é±ïŒBrandt 2009ïŒïŒ85æ¥ïŒ
- å¥ã®ç ç©¶ã§ã¯15.3é±ïŒKane 2009ïŒïŒ107æ¥ïŒ
- ããã«å¥ã®ç ç©¶ã§ã¯å¹æã®æç¶æéã®äžå€®å€ã117æ¥ïŒMonheit 2019ïŒ
DaxibotulinumtoxinA
60Uã®æäžã«ãããå¹æã®æç¶æéã22.5é±ã23.2é±ã«éãããšå ±åãããŠããŸããå補å€ã®20Uã§ã¯20.8é±ã40UïŒCarruthers 2017ïŒã§ã¯22.80é±ãšããé·æéã®æç¶ã瀺ãããŠããŸãã
NewBontAïŒProsigne®ãªã©ïŒ
NewBontA 20Uã®æç¶æéã¯12é±ïŒ84.5 ± 38.8æ¥ïŒã§ãããæ¯èŒãããOnabotulinumtoxinA 20UïŒWon 2013ïŒã®12.8é±ïŒ89.9 ± 41.1æ¥ïŒãšã»ãŒåçã§ããã
ãé¡ã暪ãžã¯ã¯113ã125æ¥ââçšéå·®ã¯ããã
é¡ã®æšªãžã¯ããããã¯ã¹ã®ä»£è¡šçãªæ²»çéšäœã§ããçéãšåæ§ã«ãçšéãå€ãã»ã©æç¶ãããã®ã®ããã®å·®ã¯éå®çã§ãã
OnabotulinumtoxinA 40Uãæäžããå Žåãå»åž«è©äŸ¡ã«ããæ²»çå¹æã®æç¶æéã¯118.5æ¥ãæ£è èªèº«ã®è©äŸ¡ã«ããæç¶æéã¯125æ¥ãäžæ¹ã30Uãæäžããã°ã«ãŒãã§ã¯ãå»åž«è©äŸ¡ã§113.0æ¥ãæ£è è©äŸ¡ã§115.5æ¥ïŒSolish 2016ïŒã§ããã
40Uãš30Uã®å·®ã¯ããã5ã10æ¥ãçšéãšæç¶æéã®é¢ä¿ã¯ãããã§ããåçãªæ¯äŸé¢ä¿ãã§ã¯ãªãããšãããããŸãã
ãç®å°»ãç¬ããžã¯ã¯æå€§157æ¥ââæ¥æ¬äººããŒã¿ããã
ç¬ã£ããšãã«ã§ããç®å°»ã®ããããããããç¬ããžã¯ãããã®éšäœã®ããŒã¿ã¯ãå®ã¯ç ç©¶ã«ãã£ãŠããªããã©ã€ãããããŸãã
- OnabotulinumtoxinA 24UïŒCarruthers 2014ïŒïŒå»åž«è©äŸ¡ã§16.8é±ïŒ118æ¥ïŒãæ£è è©äŸ¡ã§16.5é±ïŒ116æ¥ïŒãããŒã¹ã©ã€ã³ããå°ãªããšã1段éã®æ¹åãèŠãããæ£è ã§ã¯ãå»åž«è©äŸ¡ã§17.8é±ïŒ125æ¥ïŒãæ£è è©äŸ¡ã§20.5é±ïŒ144æ¥ïŒ
- å¥ã®ç ç©¶ã§ã¯ãOnabotulinumtoxinA 24UïŒWu 2019ïŒã®å¹æã®æç¶æéã¯å»åž«è©äŸ¡ã»æ£è è©äŸ¡ãšãã«çŽ150ã157æ¥
- æ¥æ¬äººå¯Ÿè±¡ã®ç ç©¶ã§ã¯ãOnabotulinumtoxinA 24UïŒHarii 2017ïŒã®æç¶æéã¯çŽ95æ¥ïŒ12Uã§ã¯85æ¥ïŒ
æ¥æ¬äººããŒã¿ã瀺ãçŽ95æ¥ãšããæ°åã¯ãæµ·å€ããŒã¿ã®150æ¥è¶ ãšæ¯ã¹ãŠçããããã¯äœæ Œå·®ã»çèéã®éãã圱é¿ããŠããå¯èœæ§ããããŸããèªåã®ããŒã¿ãšããŠåèã«ãã¹ãã¯ãåã人皮ã®ããŒã¿ã§ããããšãèŠããŠãããŠãã ããã
ãå£åšããåç¬ã§ã¯9.9é±ââã§ããã¢ã«ãã³é žãšçµã¿åããããš15.5é±ã«
ããã§ãç¥ããªããšæãããçµã¿åããã®è©±ãããŸãã
å£åšãã®ããã¯ä»ã®éšäœãšæ¯ã¹ãŠæç¶æéãããçãââããã¯äºå®ã§ããOnabotulinumtoxinAãåç¬ã§9UïŒCarruthers 2010ïŒæäžããå Žåã®å¹³å广æç¶æéã¯9.9é±ïŒ69.3 ± 11.0æ¥ïŒã
ãšããããåã9Uã®OnabotulinumtoxinAã«ãã¢ã«ãã³é žïŒJUVEDERM ULTRA®ãªã©ïŒã䜵çšããå Žåãæç¶æéã¯15.5é±ïŒ108.9 ± 12æ¥ïŒãžãšå€§å¹ ã«å»¶é·ãããŸããïŒCarruthers 2010ïŒã
9.9é± â 15.5é±ãçŽ56%ã®å»¶é·ã§ãã
å£åšãã®æ·±ãããã«å¯ŸããŠã¯ãçèã®åããæãããããã¯ã¹ãšæºãåãããã¢ã«ãã³é žã®ã³ã³ãããŒã·ã§ã³æ²»çãéåžžã«æå¹ã§ããããããã¯ã¹ã ããã§å£åšãã®ãããæ²»ãããšããŠããæ¹ã¯ãäžåºŠå»åž«ã«äœµçšã®å¯èœæ§ãèããŠã¿ã䟡å€ããããŸãã
ããšã©ïŒå¬çïŒãç¹°ãè¿ã泚å°ã¯èŠæ³šæââ6ã¶æåŸãæ©èœãå埩ããªãããŒã¿ãã
ãšã©ãžã®ãããã¯ã¹ã«ã¯ãä»ã®éšäœã«ã¯ãªããªã¹ã¯ããããŸãããããç¥ããã«ç¹°ãè¿ã泚å°ããŠããæ¹ã¯ãèªã¿é£ã°ããªãã§ãã ããã
ãšã©ïŒå¬çè¥å€§ïŒã«å¯Ÿãããããã¯ã¹æ³šå°ã¯ãé¡ã®èŒªéãã·ã£ãŒãã«ããå°é¡ç®çããæ¯ãããã»é£ããã°ãã®æ²»çç®çã§éåžžã«äººæ°ããããŸããããããå¬çãžã®æ³šå°ã«ã¯ä»ã®éšäœãšã¯ç°ãªã泚æç¹ãååšããŸãã
ååæ³šå°ãšç¹°ãè¿ã泚å°ââããŒã¿ãç€ºãæ·±å»ãªå·®
26人ïŒSouza Nobre 2024ïŒã®å¥³æ§ã察象ãšããèšåºè©Šéšã§ã¯ãåå¬çã«75UïŒSouza Nobre 2024ïŒã®AbobotulinumtoxinãæäžãããŸãããååã®äœçšéBontA泚å°ã¯çèã®åã¿ã«å¯ŸããŠæ°žä¹ çãªåœ±é¿ãäžããªããšèããããŠãããè¶ é³æ³¢æ€æ»ã«ããè©äŸ¡ã§ã3ã¶æïŒSouza Nobre 2024ïŒåŸã«ã¯åã¿ãå埩ãå§ããŠããããšã確èªãããŠããŸãã
ãããããéèŠã§ãã
ååæ³šå°ãã3ã¶æïŒSouza Nobre 2024ïŒåŸã«è¿œå ã®ããŒã¹ã¿ãŒæ³šå°ãè¡ã£ãã°ã«ãŒãã§ã¯ã2åç®ã®æ³šå°ãã3ã¶æïŒååããåèš6ã¶æïŒãçµéããŠããçèã®åã¿ã¯æ£åžžã«æ»ããŸããã§ããïŒSouza Nobre 2024ïŒãããã¯ãç¥çµæ¯é ã®å埩ãäžå®å šã§ãã£ãããçèç·ç¶ã®èçž®ãé²è¡ããçµæã§ããå¯èœæ§ãææãããŠããŸãã
ååŒæ©èœãžã®é·æç圱é¿ââãåãåããåå¹Žä»¥äžæ»ããªã
å¬ååïŒåãåïŒãååæ³šå°ã§ããã°3ã¶æïŒSouza Nobre 2024ïŒã§åŸã ã«æ£åžžã«æ»ããŸãããšãããã3ã¶æåŸã«è¿œå 泚å°ãè¡ã£ãå Žåã6ã¶æã®è¿œè·¡èª¿æ»æç¹ã§ãçèã®æŽ»åã¯å埩ããŸããã§ããïŒSouza Nobre 2024ïŒããŸããååŒããã©ãŒãã³ã¹ïŒåã¿ç ãèœåïŒã«é¢ããŠããååæ³šå°ããã³3ã¶æåŸã®è¿œå 泚å°ã®äž¡æ¹ã«ãããŠã6ã¶æã®è¿œè·¡æéäžãã£ãšæ©èœãäœäžãããŸãŸã§ããïŒSouza Nobre 2024ïŒã
çŸå®¹ç®çã®ã¿ã§å¬çã«ãããã¯ã¹ãç¹°ãè¿ã泚å°ããå Žåãçèã®èçž®ãååŒæ©èœã®äœäžãšãã£ãæ©èœçãªæªåœ±é¿ãé·åŒãå¯èœæ§ããããããæ²»çééã«ã¯ååãªæ³šæãå¿ èŠã§ãã
æç¶æéãå·Šå³ãããã1ã€ã®èŠå ââãæ§å¥ãã§çŽ25æ¥å€ãã
éšäœãšè£œå€ã ããæç¶æéãæ±ºããããã§ã¯ãããŸãããããªããç·æ§ã女æ§ãã«ãã£ãŠããå¹æã®æç¶æéã¯å€§ããå€ãããŸãã
äžè¬çã«ãç·æ§ã¯å¥³æ§ãããçèãçºéããŠãã匷ãåãæã£ãŠããŸãããã®äºå®ã¯ãã·ã¯ãæ²»çããããã«å¿ èŠãªBontAã®åäœæ°ããå¹æã®æç¶æéã«çŽæ¥çã«åœ±é¿ãäžããå¯èœæ§ããããŸãïŒCochrane Review 2021ïŒã
æ°åã§èŠããšããã®å·®ã¯äžç®çç¶ã§ãã
IncobotulinumtoxinAãæäžãããã°ã«ãŒãã«ãããŠãæ²»çå¹æã®æç¶æéã¯å¥³æ§ã§146.12æ¥ã§ãã£ãã®ã«å¯Ÿããç·æ§ã§ã¯121.14æ¥ãšçŽ25æ¥çããªããŸãããåæ§ã«ãOnabotulinumtoxinAãæäžãããã°ã«ãŒãã§ãã女æ§ã®æç¶æéã¯140.65æ¥ã§ãã£ãã®ã«å¯Ÿããç·æ§ã¯116.61æ¥ïŒRappl 2013ïŒãšããçµæãåºãŠããŸãã
ç·æ§ã§ããªãèªåã¯æ©ãåããæ°ãããã®ãããšæããŠããæ¹ââããã¯æ°ã®ããã§ã¯ãªããè«æã§è£ä»ããããããŒã¿ã§ããç·æ§ã®å Žåãéåžžãããé«çšéã®æäžãçãééã§ã®æ²»çãå¿ èŠã«ãªãã±ãŒã¹ããããŸãã
ãŸãšãïŒéšäœå¥ã»æç¶æéããŒã¿äžèЧ
ãããŸã§èªãã ããªãã¯ãã人ããããããšããææ§ãªèšèã«æããããå¿ èŠããªããªããŸãããè«æããŒã¿ã瀺ãäºå®ããæåŸã«æŽçããŠãããŸãã
- çéã®ããïŒ çšéã«ããç°ãªãããæŠã17é±ïŒCarruthers 2005aïŒãã24é±ïŒCarruthers 2005aïŒçšåºŠæç¶ãããé«çšéïŒ80UïŒãæäžããã°24.2é±ãã€ããçšéã«å®å šã«æ¯äŸããããã§ã¯ãªãã
- ç®å°»ã®ããïŒ æŠã16é±ïŒ116æ¥ã118æ¥ïŒãã20é±ïŒçŽ144æ¥ïŒçšåºŠæç¶ããïŒCarruthers 2014ïŒã
- é¡ã®ããïŒ 30Uãã40Uã®æäžã§ãçŽ113æ¥ãã125æ¥æç¶ããïŒSolish 2016ïŒã
- å£åšãã®ããïŒ ãããã¯ã¹åç¬ã§ã¯9.9é±ãšæ¯èŒççããããã¢ã«ãã³é žã䜵çšããããšã§15.5é±ïŒCarruthers 2010ïŒãžãšçŽ56%æç¶æéãå»¶ã°ãããšãã§ããã
- ãšã©ïŒå¬çïŒïŒ ååæ³šå°ã§ã¯3ã¶æçšåºŠã§å埩ãå§ããããçãééã§ç¹°ãè¿ã泚å°ãè¡ããšãçèã®èçž®ãååŒæ©èœã®äœäžãšãã£ãæªåœ±é¿ã6ã¶æä»¥äžé·åŒãå¯èœæ§ãããïŒSouza Nobre 2024ïŒã
- æ§å¥ã®åœ±é¿ïŒ ç·æ§ã¯çèã®åã匷ãããã女æ§ãšæ¯ã¹ãŠãããã¯ã¹ã®å¹ææç¶æéãçŽ25æ¥çããªãåŸåãããïŒRappl 2013ïŒã
ãããã¯ã¹ã¯å®å šã§å¹æçãªæ²»çæ³ã§ããããã®äœçšæ©åºãéšäœã«ããç¹æ§ãããã«ã¯èªèº«ã®çèã®åŒ·ãïŒæ§å¥ãªã©ïŒãçè§£ããŠããããšã§ãããæºè¶³åºŠã®é«ãæ²»çèšç»ãç«ãŠãããšãã§ããŸããæ¬¡åã®ã¯ãªããã¯å蚺ã®éã«ã¯ããããã®ããŒã¿ãåèã«ãå»åž«ãšé©åãªæäžéãæ²»çã¹ã±ãžã¥ãŒã«ã«ã€ããŠçžè«ããŠã¿ãŠãã ããã
ãç§ã®å Žåã¯ã©ãã ããïŒããšæã£ãã
ç¡æã«ãŠã³ã»ãªã³ã°ãäºçŽãã
ç¡çãªå§èªã¯ããããŸããããæ°è»œã«ã©ããã
åèæç®
- Gostimir M et al. Safety of Botulinum Toxin A Injections for Facial Rejuvenation: A Meta-Analysis of 9,669 Patients. Ophthalmic Plast Reconstr Surg. 2023
- Carruthers J, Carruthers A. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes. Dermatol Surg. 2007
- Carruthers J et al. Injectable daxibotulinumtoxinA for glabellar lines. Dermatol Surg. 2017
ãã®èšäºãæžãã人
äžæ å®å éåº§é¢ å»åž«
Zetith Beauty Clinic é座é¢ã»å€§éªå¿ææ©é¢ã»çŠå²¡é¢
æ¥æ¬åœå ããã³åœéåŠäŒã§ã®ç ç©¶çºè¡šå®çžŸãæã¡ãZetith Beauty Clinicå šäœã®æè¡æå°ã»æè²ã«ãæºãããè§£ååŠçæ ¹æ ã«åºã¥ãã粟å¯ãªçŸå®¹å»çãå°éãšããäžäººã²ãšãã®éªšæ Œãçµç¹ã«åãããèªç¶ãªä»äžããã远æ±ããŠããã